Qualigen Therapeutics, Inc. — Director's Dealing 2020

Apr 23, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RITTER PHARMACEUTICALS INC (RTTR)
CIK: 0001460702
Period of Report: 2020-01-21

Reporting Person: FOEHR MATTHEW W (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-21	Common Stock	C	76923	—	Acquired	100174	Direct
2020-04-10	Common Stock	A	38461	—	Acquired	138635	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-21	Series B convertible preferred stock	$1.30	C	100	Disposed		Common Stock (76923)	Direct
2020-04-10	Warrant Shares (right to buy)	$1.30	D	38461	Disposed	2023-11-05	Common Stock (38461)	Direct

Footnotes

F1: The Reporting Person converted 100 shares of Series B convertible preferred stock on January 21, 2020, at a conversion price of $1.30 per share, resulting in his acquisition of 76,923 shares of common stock. The Series B convertible preferred stock had a stated value of $1,000 per share, was convertible at any time, and had no expiration date.

F2: The Reporting Person disposed of warrants to purchase 38,461 shares of the Issuer's common stock in exchange for 38,461 shares of the Issuer's common stock pursuant to an exchange agreement with the Issuer in reliance on Section 3(a)(9) of the Securities Act of 1933, as amended.